Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus

Bartsch, Thorsten; Levy, Miles; Knight, Yolande E.; Goadsby, PJ

doi:10.1016/j.pain.2005.05.015

Cited by 64 publications

(42 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Manipulation of the posterior hypothalamic somatostatin receptors modulates dural and facial trigeminal nociceptive transmission in the TNC. Microinjection of cyclosomatostatin into the posterior hypothalamus inhibited both A-and C-fi ber responses to dural electrical stimulation and decreased their response to noxious thermal facial stimulation [60].…”

Section: Other Hypothalamic Peptide Hormonesmentioning

confidence: 93%

Cluster headache, hypothalamus, and orexin

Holland

Goadsby²

2009

Current Science Inc

View full text Add to dashboard Cite

Cluster headache (CH) is a highly disabling condition resulting in severe, recurrent unilateral bouts of pain and accompanying autonomic symptoms. This review describes some current views regarding the underlying pathophysiology covering the pain and cranial autonomic (parasympathetic) activation, and highlights the potential importance of the hypothalamus in CH. The hypothalamus is known to modulate many functions and has been shown to be involved in the pathophysiology of a variety of primary headaches, including CH. Hypothalamic structures are likely to underlie the circadian and circannual periodicity of attacks and contribute to the pain and autonomic disturbances. We discuss the hypothalamic involvement in CH and modulation of trigeminovascular processing and examine the emerging involvement of the hypothalamic orexinergic system as a possible key pathway in CH pathophysiology.

show abstract

Section: Other Hypothalamic Peptide Hormonesmentioning

confidence: 93%

Cluster headache, hypothalamus, and orexin

Holland

Goadsby²

2009

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…Microinjection of cyclo-somatostatin into the posterior hypothalamus inhibited both A-and C-fiber responses to dural electrical stimulation and decreased their response to noxious thermal facial stimulation [42]. The somatostatin analogue octreotide is an effective abortive agent for CH [43].…”

Section: The Hypothalamus and The Putative Mechanisms Of Nociceptionmentioning

confidence: 99%

Functional and structural neuroimaging in trigeminal autonomic cephalalgias

Matharu

May²

2008

Current Science Inc

View full text Add to dashboard Cite

The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features. They include cluster headache, paroxysmal hemicrania, and short-lasting unilateral neuralgiform headache with conjunctival injection and tearing. Until recently, primary headache disorders, including the TACs, were widely considered to be caused by peripheral mechanisms such as vascular changes or neurogenic inflammation. Developments in neuroimaging are revolutionizing our understanding of the pathophysiology of primary headache syndromes. Functional imaging studies have demonstrated hypothalamic activation in all the TACs. Furthermore, neuroimaging studies using voxel-based morphometry and magnetic resonance spectroscopy techniques have demonstrated structural and biochemical alterations, respectively, in the hypothalamus of patients with cluster headache. These studies suggest that the hypothalamus plays a crucial role in the pathophysiology of TACs, thereby supporting the notion that these disorders are primarily due to central rather than peripheral mechanisms.

show abstract

“…Our data provide pharmacological evidence for an opioid receptor agonist effect of CSST; no sign of antagonist action was found, at least not against morphine. Opioid agonist activity of CSST might explain some in vivo findings, such as an antinociceptive effect of central administration of this peptide (Bartsch et al, 2005).…”

Section: Discussionmentioning

confidence: 99%